Abstract 4474

Introdution:

Previously, leukemic stem cells in Chronic Myelogenous Leukemia could only be identified indirectly by using culture techniques. Jeroen J.W et al have developed a new flow cytometric approach that allows a direct discrimination of CML stem cells from their normal counterparts within single patient samples. CD34+CD38- leukemic stem cells could be discriminated from normal stem cells by high CD90 expression, which is a specific feature of CML stem cells, while CD90 expression is low on their normal counterparts.

Material: A total of 8 patients and 3 health controls were included in this study.

Result:

Health controls did not present CD90 molecular expression in stem cells. 100% of the patients presented different levels of CD90 in CD34+/CD38- cells. Our patients seemed to show an asociation between CD34+/CD38- stem cells which express CD90+ and bcr-abl levels. We have evolutive studies of 4 patients who are under treatment with imatinib; in those patients we apreciate decrease in the level of CD90 related to good response.

Conclusion:

Our results confirm Jeroen's data; we think that this new technique will expand our possibilities to identify CML stem cell specific targets and may improve efficacy assessment of CML treatment as well.

Disclosures:

García:Celgene: Research Funding.

Topics:
bcr-abl tyrosine kinase, imatinib mesylate, leukemia, myelocytic, chronic, leukemic hematopoietic stem cell, stem cells, cd38, disclosure, research funding

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2010 by The American Society of Hematology
2010
Sign in via your Institution